[Disclosure] Alteogen (196170) to Acquire 1.05M New Shares of Altos Biologics Due to Subsidiary Merger, Resulting in 62.89% Stake

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-04-03

Disclosure Type: Decision on Acquisition of Shares and Investment Certificates of Other Corporations

💡 3-Second Summary

Alteogen will acquire 1,059,695 newly issued shares (valued at approx. KRW 39.88B) of its subsidiary, Altos Biologics, as a result of merging two of its subsidiaries to consolidate corporate structure. Since this is an intra-group merger allocation, no additional cash outflow will be incurred by Alteogen.

📊 1. [Summary of Core Disclosure Content and Key Figures]

• Target Target: Altos Biologics Inc. (A subsidiary of Alteogen; Core business: Pharmaceutical R&D)
• Shares and Amount to be Acquired: 1,059,695 Common Shares / KRW 39,876,322,850
• Financial Metrics: The acquisition amount represents 13.24% of Alteogen’s equity capital (approx. KRW 301.1B) and 12.02% of its total assets at the end of the prior fiscal year (approx. KRW 331.6B).
• Total Ownership Post-Acquisition: 6,059,695 shares (Ownership ratio: 62.89%)
• Method and Purpose: Acquisition of new shares through an intra-group merger (Surviving entity: Altos Biologics Inc., Extinguished entity: Alteogen Healthcare Inc.) to maximize operational synergy and corporate management efficiency.
• Scheduled Acquisition Date: May 23, 2025
• Payment and Transaction Terms: As an assignment derived from an intra-group consolidation, no separate cash consideration or individual purchase payment is required. Accounting adjustments will be limited to aggregating the carrying value of subsidiary investments. (The amount was calculated by multiplying the allocated shares by the merger baseline price of KRW 37,630).
• Board Resolution Date: April 3, 2025 (Attended by the auditor)
• Summary Financial Status of Target Entity (Current Fiscal Year): Total Assets of KRW 87,464M, Total Liabilities of KRW 10,530M, Total Equity of KRW 76,934M, Revenue of KRW 0M (-), Net Income of KRW -4,561M (Net Loss).

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This operational disclosure functions as an administrative tracking notification regarding ownership adjustments arising from an internal reorganization, where Alteogen merges its sub-entities, Altos Biologics and Alteogen Healthcare. Although the filing registers a transaction volume of approximately KRW 39.88B (13.24% of equity capital), it represents a technical exchange of equity from the dissolved entity into new shares of the surviving entity, thus generating no near-term asset outflow or distinct variations in Alteogen’s standalone income statements.

Investors should analyze this development strictly as an internal organizational streamline rather than an external commercial expansion. Any forward-looking influence regarding consolidated overhead reductions or long-term operational performance remains speculative, and investors should avoid treating this reorganization as an definitive driver of earnings growth. It is practical to prioritize the documented timeline, such as the scheduled effective date of May 23, 2025, and understand the structural equity re-allocations without adding non-disclosed parameters to the core business fundamentals.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen has initiated an internal corporate reorganization by merging its sub-units, Altos Biologics and Alteogen Healthcare. While the headline figures highlighting a KRW 39.8B transaction might initially appear as an extensive new capital investment, it is an administrative accounting consolidation without actual cash drainage from the parent company. Upon the cancellation of the dissolved unit, Alteogen receives new shares from Altos Biologics, moving its final ownership to 62.89%. The target entity currently reports no revenue and a net loss of approximately KRW 4.56B for the current year; thus, market players should monitor the integration process objectively based purely on official metrics.

📢 Disclaimer and Source Information

Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.